Telomerase reverse transcriptase mutation and the p53 pathway in T1 urinary bladder cancer. (4th July 2021)

• Record Type: Journal Article
• Authors: Jahnson, Staffan; Söderkvist, Peter; Aljabery, Firas; Olsson, Hans
• Is Part Of: BJU international. Volume 129:Number 5(2022)
• Page Start: 601
• Page End: 609
• Publication Date: 2021-07-04
• Subjects: TERT mutation -- p53 pathway -- urinary bladder cancer -- p53 immunohistochemistry -- p53 mutation -- #BladderCancer -- #blcsm; Genitourinary organs -- Diseases -- Periodicals; Genitourinary organs -- Surgery -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1111/bju.15490
• Languages: English
• ISSNs: 1464-4096

Abstract

Abstract : Objective: To study the telomerase reverse transcriptase (TERT) mutation and the p53 pathway in T1 urinary bladder cancer (UBC). Materials and Methods: This prospectively performed population‐based study included all patients in the Southeast Healthcare Region in Sweden with T1 UBC registered in the period 1992–2001, inclusive. Given that p53 and TERT are important factors for tumour proliferation, although their interrelationships are unknown, we assessed both the TERT and the p53 mutations. Furthermore, we conducted a p53 immunohistochemistry (IHC) analysis using two thresholds for p53 positivity: 10% of tumour cells and 50% of tumour cells (p53 IHC50%). Cox proportional hazards analysis and Kaplan–Meier curves were used to study time to tumour progression. Results: Out of 158 patients, we observed the TERT mutation in 74 (47%), the p53 mutation in 48 (30%), and p53 IHC50% positivity in 72 patients (46%). The TERT mutation was more common in p53 mutation‐positive patients ( P = 0.009), and the latter group also had more patients with p53 IHC50%‐positive tumour cells ( P = 0.02). In the TERT mutation‐negative tumours a p53‐positive mutation was associated with a shorter time to progression ( P = 0.03) compared to patients with p53‐negative mutation. In contrast, in tumours with both TERT mutation positivity and p53 mutation positivity, a longer time to progression was observed in the group with p53 IHC50% positivity compared to the group with p53 IHC50%‐negative tumours. Conclusions: In stage T1 UBC, the combination of the TERT mutation and the p53 mutation was associated with tumour progression. A protective effect of the TERT promotor mutation against tumour progression induced by the p53 mutation and subsequent p53 accumulation in tumour cells might be possible, but further investigations are necessary.